| Primary |
| Gout |
73.8% |
| Hyperuricaemia |
6.3% |
| Blood Uric Acid Increased |
4.6% |
| Drug Use For Unknown Indication |
4.3% |
| Gouty Tophus |
2.3% |
| Influenza Immunisation |
1.0% |
| Renal Transplant |
1.0% |
| Supplementation Therapy |
1.0% |
| Atrial Fibrillation |
0.7% |
| Helicobacter Infection |
0.7% |
| Immunosuppression |
0.7% |
| Pain |
0.7% |
| Type 2 Diabetes Mellitus |
0.7% |
| Antiviral Prophylaxis |
0.3% |
| Blood Uric Acid |
0.3% |
| Calculus Urinary |
0.3% |
| Cardiac Failure Congestive |
0.3% |
| Chronic Obstructive Pulmonary Disease |
0.3% |
| Condition Aggravated |
0.3% |
| Diabetes Mellitus |
0.3% |
|
| Death |
9.9% |
| Stevens-johnson Syndrome |
9.1% |
| Myocardial Infarction |
8.3% |
| Pulmonary Embolism |
6.6% |
| Rash |
6.6% |
| Rhabdomyolysis |
5.8% |
| Cerebrovascular Accident |
5.0% |
| Gout |
5.0% |
| Hepatic Failure |
5.0% |
| Oedema Peripheral |
5.0% |
| Cardiac Failure Congestive |
4.1% |
| Dyspnoea |
4.1% |
| Sepsis |
4.1% |
| Pyrexia |
3.3% |
| Renal Failure Acute |
3.3% |
| Thrombocytopenia |
3.3% |
| Unresponsive To Stimuli |
3.3% |
| White Blood Cell Count Increased |
3.3% |
| Erythema |
2.5% |
| Jaundice |
2.5% |
|
| Secondary |
| Gout |
46.9% |
| Product Used For Unknown Indication |
7.7% |
| Drug Use For Unknown Indication |
7.2% |
| Pain |
6.2% |
| Hypertension |
5.7% |
| Blood Uric Acid |
2.6% |
| Diabetes Mellitus |
2.6% |
| Atrial Fibrillation |
2.1% |
| Blood Uric Acid Increased |
2.1% |
| Gastric Ulcer |
2.1% |
| Type 2 Diabetes Mellitus |
2.1% |
| Blood Cholesterol Increased |
1.5% |
| Cardiac Disorder |
1.5% |
| Helicobacter Gastritis |
1.5% |
| Helicobacter Infection |
1.5% |
| Hyperuricaemia |
1.5% |
| Prophylaxis |
1.5% |
| Renal Transplant |
1.5% |
| Cardiac Failure Congestive |
1.0% |
| Coagulopathy |
1.0% |
|
| Confusional State |
9.5% |
| Diarrhoea |
9.5% |
| Vomiting |
9.5% |
| Rash |
7.1% |
| Toxic Epidermal Necrolysis |
7.1% |
| Frequent Bowel Movements |
4.8% |
| Myocardial Infarction |
4.8% |
| Renal Failure |
4.8% |
| Renal Failure Acute |
4.8% |
| Renal Impairment |
4.8% |
| Respiratory Failure |
4.8% |
| Rhabdomyolysis |
4.8% |
| Tachycardia |
4.8% |
| Thrombocytopenia |
4.8% |
| Acute Generalised Exanthematous Pustulosis |
2.4% |
| Arthralgia |
2.4% |
| Asthenia |
2.4% |
| Blood Uric Acid Increased |
2.4% |
| Condition Aggravated |
2.4% |
| Drug Hypersensitivity |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.9% |
| Gout |
13.5% |
| Hypertension |
6.9% |
| Premedication |
5.5% |
| Atrial Fibrillation |
3.2% |
| Drug Use For Unknown Indication |
2.6% |
| Prophylaxis |
2.5% |
| Pain |
2.1% |
| Type 2 Diabetes Mellitus |
1.9% |
| Diabetes Mellitus |
1.8% |
| Psoriasis |
1.8% |
| Blood Cholesterol Increased |
1.7% |
| Rheumatoid Arthritis |
1.6% |
| Blood Pressure |
1.4% |
| Cardiac Disorder |
1.4% |
| Crohn's Disease |
1.3% |
| Gouty Tophus |
1.1% |
| Renal Transplant |
0.9% |
| Blood Cholesterol |
0.9% |
| High Density Lipoprotein Decreased |
0.9% |
|
| Therapeutic Response Decreased |
11.3% |
| Death |
10.5% |
| Infusion Related Reaction |
7.5% |
| Weight Increased |
6.0% |
| Arthralgia |
5.3% |
| Diarrhoea |
5.3% |
| Gout |
5.3% |
| Pain In Extremity |
5.3% |
| Drug Ineffective |
4.5% |
| Flushing |
4.5% |
| Weight Decreased |
4.5% |
| Fatigue |
3.8% |
| Nausea |
3.8% |
| Off Label Use |
3.8% |
| Renal Failure |
3.8% |
| Blood Glucose Increased |
3.0% |
| Blood Pressure Increased |
3.0% |
| Cardiac Disorder |
3.0% |
| Injection Site Pain |
3.0% |
| Lipase Increased |
3.0% |
|
| Interacting |
| Renal Disorder |
33.3% |
| Arthritis |
11.1% |
| Breakthrough Pain |
11.1% |
| Flatulence |
11.1% |
| Hypertension |
11.1% |
| Nocturia |
11.1% |
| Product Used For Unknown Indication |
11.1% |
|
| Poor Quality Drug Administered |
50.0% |
| Therapeutic Response Decreased |
50.0% |
|
